Manz Theresa D, Sivakumaren Sindhu C, Yasgar Adam, Hall Matthew D, Davis Mindy I, Seo Hyuk-Soo, Card Joseph D, Ficarro Scott B, Shim Hyeseok, Marto Jarrod A, Dhe-Paganon Sirano, Sasaki Atsuo T, Boxer Matthew B, Simeonov Anton, Cantley Lewis C, Shen Min, Zhang Tinghu, Ferguson Fleur M, Gray Nathanael S
Department of Cancer Biology, Dana-Farber Cancer Institute, 360 Longwood Avenue, Boston, Massachusetts 02215, United States.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.
ACS Med Chem Lett. 2019 Nov 3;11(3):346-352. doi: 10.1021/acsmedchemlett.9b00402. eCollection 2020 Mar 12.
Phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are important molecular players in a variety of diseases, such as cancer. Currently available PI5P4K inhibitors are reversible small molecules, which may lack selectivity and sufficient cellular on-target activity. In this study, we present a new class of covalent pan-PI5P4K inhibitors with potent biochemical and cellular activity. Our designs are based on THZ-P1-2, a covalent PI5P4K inhibitor previously developed in our lab. Here, we report further structure-guided optimization and structure-activity relationship (SAR) study of this scaffold, resulting in compound , which retained biochemical and cellular potency, while demonstrating a significantly improved selectivity profile. Furthermore, we confirm that the inhibitors show efficient binding affinity in the context of HEK 293T cells using isothermal CETSA methods. Taken together, compound represents a highly selective pan-PI5P4K covalent lead molecule.
磷脂酰肌醇5-磷酸4-激酶(PI5P4K)是多种疾病(如癌症)中的重要分子参与者。目前可用的PI5P4K抑制剂是可逆的小分子,可能缺乏选择性和足够的细胞靶向活性。在本研究中,我们提出了一类具有强大生化和细胞活性的新型共价泛PI5P4K抑制剂。我们的设计基于THZ-P1-2,这是我们实验室之前开发的一种共价PI5P4K抑制剂。在此,我们报告了对该支架的进一步结构导向优化和构效关系(SAR)研究,得到了化合物 ,其保留了生化和细胞活性,同时显示出显著改善的选择性。此外,我们使用等温CETSA方法证实了这些抑制剂在HEK 293T细胞环境中显示出有效的结合亲和力。综上所述,化合物 代表了一种高度选择性的泛PI5P4K共价先导分子。